Condition: Hepato Cellular Carcinoma (HCC) · Sponsor: Fudan University
This study will evaluate the efficacy and safety of therapy perioperative treatment with HAIC combined with donafenib and sintilimab (group A)/ donafenib combined with sintilimab (group B) compared with direct surgery (group C) in resectable HCC patients who are at high risk for disease recurrence.
This description comes directly from the study's public registry record.
Lu Wang, M.D. · 86-18121299357 · w.lr@hotmail.com
Always discuss trial participation with your own doctor first.
| Fujian Cancer Hospital | Fuzhou, Fujian, China | Not Yet Recruiting |
| Fudan University Shanghai Cancer Center | Shanghai, Shanghai Municipality, China | Recruiting |
| TianJin Medical University Cancer Institute & Hospital | Tianjin, Tianjin Municipality, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06812039